A member firm of Ernst & Young Global Limited Liability limited by a scheme approved under Professional Standards Legislation Ernst & Young 8 Exhibition Street Melbourne VIC 3000 Australia GPO Box 67 Melbourne VIC 3001 Tel: +61 3 9288 8000 Fax: +61 3 8650 7777 ey.com/au Independent Limited Assurance Report to the Management and Directors of CSL Limited Our Conclusion Ernst & Young (‘EY’, ‘we’) were engaged by CSL Limited (‘CSL’) to undertake a limited assurance engagement as defined by Australian Auditing Standards, hereafter referred to as a ‘review’, over the Subject Matter defined below for the year ended 30 June 2023. Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believe the Subject Matter has not been prepared, in all material respects, in accordance with the Criteria defined below. What our review covered We reviewed CSL’s preparation and application of its materiality process against the Global Reporting Initiative (GRI) 2016 Standards’ Materiality Principle for defining reporting content, as included in CSL’s 2023 Annual Report (‘the Report’) and online at https://www.csl.com/sustainability/governance/stakeholder-engagement-and-material-topics. We also reviewed the Selected Disclosures, listed below, as disclosed in CSL’s Report, for the year ended 30 June 2023. Material topic Selected Disclosures Page Reference Health, safety and wellbeing 1. Total Recordable Incident Frequency Rate (TRIFR), non-plasma 2. Total Recordable Incident Frequency Rate (TRIFR), plasma 3. Fatalities 1. 45, 73 2. 45, 73 3. 45, 73 Product safety and quality 1. Regulatory audits, Plasma 2. Good Manufacturing Practice (GMP) manufacturing regulatory audits 3. Critical findings in Plasma and Manufacturing regulatory inspections that prevent release of commercial product 4. Safety related product recalls 1. 20, 53, 73 2. 20, 53, 73 3. 53 4. 53, 73 Communities we operate in 1. Economic value generated 2. Economic value distributed 1. 73 2. 20, 53, 73 Accessible & affordable healthcare Humanitarian aid/product assistance 20, 55, 73 Innovation & R&D Total R&D investment 10, 20, 21, 73 Talent recruitment, development and retention Employee Opinion Survey Results 20, 44, 73 CSL Limited Annual Report 2022/23 81
RkJQdWJsaXNoZXIy MjE2NDg3